Mail

UK markets closed

FTSE 100
8,213.49
+41.34(+0.51%)
FTSE 250
20,164.54
+112.21(+0.56%)
AIM
771.53
+3.42(+0.45%)
GBP/EUR
1.1652
-0.0031(-0.26%)
GBP/USD
1.2546
+0.0013(+0.11%)
Bitcoin GBP
50,172.89
+2,829.78(+5.98%)

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

Navidea Biopharmaceuticals, Inc (NAVB)

Other OTC - Other OTC Delayed price. Currency in USD

Add to watchlist

0.0382

+0.0032

(+9.29%)

At close: 02:06PM EDT

Currency in USD

Valuation measures⁴

Market cap (intra-day)	3.83M
Enterprise value	1.22M
Trailing P/E	N/A
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	3.35k
Price/book (mrq)	N/A
Enterprise value/revenue	2.01k
Enterprise value/EBITDA	-0.12

Trading information

Stock price history

Beta (5Y monthly)	1.15
52-week change ³	-78.66%
S&P500 52-week change ³	22.38%
52-week high ³	0.1941
52-week low ³	0.0210
50-day moving average ³	0.0388
200-day moving average ³	0.0574

Share statistics

Avg vol (3-month) ³	84.73k
Avg vol (10-day) ³	34.65k
Shares outstanding ⁵	100.08M
Implied shares outstanding ⁶	100.08M
Float ⁸	64.07M
% held by insiders ¹	35.89%
% held by institutions ¹	0.01%
Shares short (15 Sept 2023) ⁴	2.69M
Short ratio (15 Sept 2023) ⁴	0.52
Short % of float (15 Sept 2023) ⁴	3.96%
Short % of shares outstanding (15 Sept 2023) ⁴	2.68%
Shares short (prior month 15 Aug 2023) ⁴	534.87k

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	26 Apr 2019
Ex-dividend date ⁴	N/A
Last split factor ²	1:20
Last split date ³	26 Apr 2019

Financial highlights

Fiscal year

Fiscal year ends	31 Dec 2022
Most-recent quarter (mrq)	30 Sept 2023

Profitability

Profit margin	0.00%
Operating margin (ttm)	-1,678,791.02%

Management effectiveness

Return on assets (ttm)	-107.05%
Return on equity (ttm)	N/A

Income statement

Revenue (ttm)	610
Revenue per share (ttm)	0.00
Quarterly revenue growth (yoy)	N/A
Gross profit (ttm)	N/A
EBITDA	-10.13M
Net income avi to common (ttm)	-8.81M
Diluted EPS (ttm)	-0.2000
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	3.86M
Total cash per share (mrq)	0.04
Total debt (mrq)	1.26M
Total debt/equity (mrq)	N/A
Current ratio (mrq)	0.56
Book value per share (mrq)	-0.03

Cash flow statement

Operating cash flow (ttm)	-9.71M
Levered free cash flow (ttm)	-7.77M